Burana 600 mg – ibuprofen package<unk> s can be classified based on their chemical structure or mechanism of action. Older<unk> s were known long before their mechanism of action was elucidated and were for this reason classified by chemical structure or origin. Newer substances are more often classified by mechanism of action. Salicylates * Aspirin (acetylsalicylic acid) * Diflunisal (Dolobid) * Salicylic acid and its salts * Salsalate (Disalcid) Propionic acid derivatives * Ibuprofen * Dexibuprofen * Naproxen * Fenoprofen * Ketoprofen * Dexketoprofen * Flurbiprofen * Oxaprozin * Loxoprofen * Pelubiprofen * Zaltoprofen Acetic acid derivatives * Indomethacin * Tolmetin * Sulindac * Etodolac * Ketorolac * Diclofenac * Aceclofenac * Bromfenac * Nabumetone (drug itself is non-acidic but the active, principal metabolite has a carboxylic acid group) Enolic acid (Oxicam) derivatives * Piroxicam * Meloxicam * Tenoxicam * Droxicam * Lornoxicam * Isoxicam (withdrawn from market 1985) * Phenylbutazone (Bute) Anthranilic acid derivatives (Fenamates) The following<unk> s are derived from fenamic acid. which is a derivative of anthranilic acid, which in turn is a nitrogen isostere of salicylic acid, which is the active metabolite of aspirin. * Mefenamic acid * Meclofenamic acid * Flufenamic acid * Tolfenamic acid Selective COX-2 inhibitors (Coxibs) * Celecoxib (FDA alert) * Rofecoxib (withdrawn from market) * Valdecoxib (withdrawn from market) * Parecoxib FDA withdrawn, licensed in the EU * Lumiracoxib TGA cancelled registration * Etoricoxib not FDA approved, licensed in the EU * Firocoxib used in dogs and horses Sulfonanilides * Nimesulide (systemic preparations are banned by several countries for the potential risk of hepatotoxicity) Others * Clonixin * Licofelone acts by inhibiting LOX (lipooxygenase) and COX and hence known as 5-LOX/COX inhibitor * H-harpagide in figwort or devil's claw Chirality Most<unk> s are chiral molecules; diclofenac is a notable exception. However, the majority are prepared as racemic mixtures. Typically, only a single enantiomer is pharmacologically active. For some drugs (typically profens), an isomerase enzyme in vivo converts the inactive enantiomer into the active form, although its activity varies widely in individuals. This phenomenon is likely responsible for the poor correlation between<unk>  efficacy and plasma concentration observed in older studies when specific analysis of the active enantiomer was not performed. Ibuprofen and ketoprofen are now available in single-enantiomer preparations (dexibuprofen and dexketoprofen), which purport to offer quicker onset and an improved side-effect profile. Naproxen has always been marketed as the single active enantiomer. Main practical differences<unk> s within a group tend to have similar characteristics and tolerability. There is little difference in clinical efficacy among the<unk> s when used at equivalent doses. Rather, differences among compounds usually relate to dosing regimens (related to the compound's elimination half-life), route of administration, and tolerability profile. Regarding adverse effects, selective COX-2 inhibitors have lower risk of gastrointestinal bleeding. With the exception of naproxen, nonselective<unk> s increase the risk of having a heart attack. Some data also supports that the partially selective nabumetone is less likely to cause gastrointestinal events. A consumer report noted that ibuprofen, naproxen, and salsalate are less expensive than other<unk> s, and essentially as effective and safe when used appropriately to treat osteoarthritis and pain.
Nonsteroidal anti-inflammatory drug
Antiarthritics
Anticorticosteroid
Disease-modifying antirheumatic drug
Antiviral drug
Chiral drugs
Antiprion drug
Antiplatelet drug